ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Incidence of Oropharyngeal and Esophageal Candidiasis in Adult Kidney Transplant Recipients Receiving Nystatin versus No Prophylaxis

L. Moreno1, K. Klein1, C. Long2, R. Hall1, J. Nelson1

1Pharmacotherapy and Pharmacy Services, Pharmacotherapy Division, University Health System, The University of Texas Health Science Center at San Antonio, The University of Texas at Austin, College of Pharmacy, San Antonio, TX, 2Pharmacotherapy and Pharmacy Services, Pharmacy Practice, University Health System, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX

Meeting: 2020 American Transplant Congress

Abstract number: C-195

Keywords: Fungal infection, Prophylaxis

Session Information

Session Name: Poster Session C: Kidney Infectious Excluding Polyoma & Viral Hepatitis

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The purpose of this study is to evaluate the need for nystatin prophylaxis for oropharyngeal (OPC) and esophageal Candidiasis (EC) in adult kidney transplant recipients (KTRs), given that available guidelines currently recommend prophylaxis for 1-3 months after kidney transplant.

*Methods: A single-center retrospective analysis was conducted of adult KTRs transplanted from March 2011 to November 2018, who had 6 months of follow-up available. Compared were those who received nystatin versus no Candida prophylaxis. Patients were excluded if they were a multi-organ transplant, received an alternative antifungal for prophylaxis, lacked 6 months of follow-up, or were treated with other antifungals prior to diagnosis of OPC or EC. The primary outcome was the incidence of OPC and EC at 6 months post-transplant. Secondary outcomes included presence of and time to fungal infection after transplant and incidence of Candidiasis, Candiduria, or invasive fungal infections.

*Results: The study population included 103 KTRs, of which 53 (52%) received nystatin. Baseline characteristics were similar between groups with the exception of a higher incidence of deceased donor transplants among those in the no prophylaxis group (72% vs. 49%; p = 0.0174). The majority of patients were 51 year old (IQR 41-62 years), Hispanic (64%), dialysis patients (81%), who did not have diabetes at the time of transplant (62%) and received lymphocyte-depleting induction (76%). The average prednisone dose at discharge was 20 mg (IQR 10-25 mg) in both groups. Post-transplant, 14% of patients received corticosteroid doses > 1 mg/kg and 7% received lymphocyte-depleting agents within a year post-transplant. The nystatin group received prophylaxis for a median of 4 days (IQR 4-6 days). No OPC or EC occurred within 6 months from transplant in either group. Overall incidence of Candidiasis, Candiduria, and invasive fungal infections were 0%, 2%, and 1%, respectively. Incidence was not significantly different between groups.

*Conclusions: In adult KTRs, the use of nystatin for antifungal prophylaxis versus no prophylaxis demonstrated no incidence of OPC nor EC. In light of the current nystatin suspension shortage, these findings offer a solution. This data suggest that the use of nystatin for antifungal prophylaxis may no longer be warranted in the era of modern-day immunosuppression. However, further research is warranted to evaluate rates in patients with additional known risk factors not adequately depicted in this study such as prior colonization, neutropenia, prolonged antibiotic use, and viral co-infection.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Moreno L, Klein K, Long C, Hall R, Nelson J. Incidence of Oropharyngeal and Esophageal Candidiasis in Adult Kidney Transplant Recipients Receiving Nystatin versus No Prophylaxis [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-of-oropharyngeal-and-esophageal-candidiasis-in-adult-kidney-transplant-recipients-receiving-nystatin-versus-no-prophylaxis/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences